DUBLIN, Nov. 23, 2023 /PRNewswire/ — The “Nasal Polyps – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nasal Polyps pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
“Nasal Polyps- Pipeline Insight, 2023” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasal Polyps pipeline landscape is provided which includes the disease overview and Nasal Polyps treatment guidelines.
The assessment part of the report embraces, in depth Nasal Polyps commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasal Polyps collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Nasal Polyps R&D. The therapies under development are focused on novel approaches to treat/improve Nasal Polyps.
Nasal Polyps Emerging Drugs Chapters
This segment of the Nasal Polyps report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nasal Polyps: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasal Polyps therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasal Polyps drugs.
Nasal Polyps Emerging Drugs
Tezepelumab: AstraZeneca
Tezepelumab is being developed by AstraZeneca in collaboration with Amgen as a potential first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and other types of airway inflammation associated with severe asthma.
TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control.
Tezepelumab acts at the top of the inflammation cascade and has the potential to help address a broad population of severe asthma patients irrespective of biomarker levels. Currently the drug is in Phase III stage of its development for the treatment of Chronic Rhinosinusitis with Nasal Polyps.
Nasal Polyps: Therapeutic Assessment
This segment of the report provides insights about the different Nasal Polyps drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Nasal Polyps
There are approx. 4+ key companies which are developing the therapies for Nasal Polyps. The companies which have their Nasal Polyps drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
Key Questions Answered
- How many companies are developing Nasal Polyps drugs?
- How many Nasal Polyps drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasal Polyps?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nasal Polyps therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nasal Polyps and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- AstraZeneca
- KeyMed Biosciences
Key Products
- CM-310
- Tezepelumab
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Nasal Polyps Report Insights
- Nasal Polyps Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Nasal Polyps Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/lfbmbr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
